FDA Grants Orphan Designation to Investigational Idiopathic Pulmonary Fibrosis Treatment

Officials with the FDA granted orphan drug designation for Reviva Pharmaceuticals’ clinical stage drug candidate, RP5063 for treatment of idiopathic pulmonary fibrosis (IPF).

The drug has shown robust efficacy in highly recognized translational animal models proven to emulate pulmonary fibrosis in humans, significantly improving survival rate and reducing inflammatory cytokines and fibrosis in the lungs of bleomycin-induced pulmonary fibrosis animal model.

The findings indicate the potential for a clinically meaningful improvement and stabilization of lung function.

“Obtaining the Orphan Drug Designation is a significant regulatory milestone as well as a notable achievement for Reviva, since it validates the significant therapeutic potential of RP5063 for the treatment of IPF,” Laxminarayan Bhat, PHD, found, president, chief executive officer, Reviva, said in a statement.

The new chemical entity involves a novel mechanism of multimodal modulation of serotonin and dopamine signaling pathways. A potent inhibitor of the 5-HT2A/2B/7 receptors, RP5063 weakens functional changes in a series of well recognized translational animal models proven to emulate pulmonary fibrosis and pulmonary arterial hypertension.

Click to continue reading on MD Magazine. 

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, discusses specialty areas experiencing innovative developments in therapies.
Two phase 3 studies evaluating the triple combination regimen met the primary endpoint of improvement in lung function in patients with at least 1 F508del mutation.
Top news of the day from across the health care landscape.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.